Janice Y Chou

List of Publications by Year
in descending order

56 papers	2,284 citations	257450 24 h-index	223800 46 g-index
56 all docs	56 docs citations	56 times ranked	2081 citing authors

#	Article	IF	Citations
1	Type I Glycogen Storage Diseases: Disorders of the Glucose-6- Phosphatase Complex. Current Molecular Medicine, 2002, 2, 121-143.	1.3	254
2	Glycogen storage disease type I and G6Pase-Î² deficiency: etiology and therapy. Nature Reviews Endocrinology, 2010, 6, 676-688.	9.6	176
3	Mutations in the glucose-6-phosphatase-Î± (G6PC) gene that cause type Ia glycogen storage disease. Human Mutation, 2008, 29, 921-930.	2.5	124
4	Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphataseâ€“Î². Journal of Clinical Investigation, 2007, 117, 784-793.	8.2	105
5	Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. Blood, 2014, 123, 2843-2853.	1.4	99
6	Type I glycogen storage diseases: disorders of the glucoseâ€6â€phosphatase/glucoseâ€6â€phosphate transporter complexes. Journal of Inherited Metabolic Disease, 2015, 38, 511-519.	3.6	90
7	Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-Î²â€“deficient neutrophils in a congenital neutropenia syndrome. Blood, 2010, 116, 2783-2792.	1.4	81
8	Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood, 2008, 111, 5704-5711.	1.4	80
9	Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood, 2010, 116, 2793-2802.	1.4	78
10	Neutropenia in type Ib glycogen storage disease. Current Opinion in Hematology, 2010, 17, 36-42.	2.5	75
11	Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage Disease Type Ia Using Gene Therapy. Molecular Therapy, 2010, 18, 1076-1084.	8.2	75
12	Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology, 2012, 56, 1719-1729.	7.3	62
13	SLC37A1 and SLC37A2 Are Phosphate-Linked, Glucose-6-Phosphate Antiporters. PLoS ONE, 2011, 6, e23157.	2.5	59
14	Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia. PLoS Genetics, 2017, 13, e1006819.	3.5	53
15	The glucoseâ€6â€phosphate transporter is a phosphateâ€linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB Journal, 2008, 22, 2206-2213.	0.5	52
16	Adeno-Associated Virus-Mediated Correction of a Canine Model of Glycogen Storage Disease Type Ia. Human Gene Therapy, 2010, 21, 903-910.	2.7	52
17	Glucose-6-phosphatase-Î², implicated in a congenital neutropenia syndrome, is essential for macrophage energy homeostasis and functionality. Blood, 2012, 119, 4047-4055.	1.4	52
18	The SLC37 Family of Sugar-Phosphate/Phosphate Exchangers. Current Topics in Membranes, 2014, 73, 357-382.	0.9	47

#	Article	IF	Citations
19	G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis. Blood, 2011, 117, 3881-3892.	1.4	42
20	Human variant glucose-6-phosphate transporter is active in microsomal transport. Human Genetics, 2000, 107, 526-529.	3.8	31
21	Oxidative stress mediates nephropathy in type Ia glycogen storage disease. Laboratory Investigation, 2010, 90, 620-629.	3.7	28
22	Gene Therapy for Type I Glycogen Storage Diseases. Current Gene Therapy, 2007, 7, 79-88.	2.0	27
23	Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. Journal of Hepatology, 2008, 48, 479-485.	3.7	26
24	The SLC37 family of phosphate-linked sugar phosphate antiporters. Molecular Aspects of Medicine, 2013, 34, 601-611.	6.4	26
25	Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-Î± activity restored are at risk of developing hepatic tumors. Molecular Genetics and Metabolism, 2017, 120, 229-234.	1.1	26
26	Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. Journal of Hepatology, 2009, 51, 909-917.	3.7	25
27	Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virusâ€“based Vector. Molecular Therapy, 2010, 18, 1592-1598.	8.2	23
28	Molecular biology and gene therapy for glycogen storage disease type Ib. Journal of Inherited Metabolic Disease, 2018, 41, 1007-1014.	3.6	23
29	Structureâ€“function study of the glucose-6-phosphate transporter, an eukaryotic antiporter deficient in glycogen storage disease type Ib. Molecular Genetics and Metabolism, 2009, 96, 32-37.	1.1	21
30	Recombinant AAV-directed gene therapy for type I glycogen storage diseases. Expert Opinion on Biological Therapy, 2011, 11, 1011-1024.	3.1	21
31	The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Molecular Genetics and Metabolism, 2013, 110, 275-280.	1.1	21
32	Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy. Human Molecular Genetics, 2017, 26, 1890-1899.	2.9	21
33	Hepatic glucose-6-phosphatase-Î± deficiency leads to metabolic reprogramming in glycogen storage disease type Ia. Biochemical and Biophysical Research Communications, 2018, 498, 925-931.	2.1	21
34	Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia. Journal of Inherited Metabolic Disease, 2018, 41, 997-1006.	3.6	21
35	Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-Î± deficiency. DMM Disease Models and Mechanisms, 2014, 7, 1083-1091.	2.4	20
36	Glycogen storage disease type Ib neutrophils exhibit impaired cell adhesion and migration. Biochemical and Biophysical Research Communications, 2017, 482, 569-574.	2.1	20

#	Article	IF	Citations
37	Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Letters, 2007, 581, 3833-3838.	2.8	19
38	Mice expressing reduced levels of hepatic glucose-6-phosphatase-Î± activity do not develop age-related insulin resistance or obesity. Human Molecular Genetics, 2015, 24, 5115-5125.	2.9	16
39	Generation of mice with a conditional allele for G6pc. Genesis, 2009, 47, 590-594.	1.6	15
40	Liver-directed gene therapy for murine glycogen storage disease type Ib. Human Molecular Genetics, 2017, 26, 4395-4405.	2.9	15
41	Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing. Molecular Therapy, 2021, 29, 1602-1610.	8.2	15
42	Minimal hepatic glucose-6-phosphatase-Î± activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia. Molecular Genetics and Metabolism Reports, 2015, 3, 28-32.	1.1	14
43	The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia. Human Molecular Genetics, 2020, 29, 834-844.	2.9	14
44	Two New Mutations in the Glucose-6-Phosphatase Gene Cause Glycogen Storage Disease in Hungarian Patients. European Journal of Human Genetics, 1997, 5, 191-195.	2.8	14
45	Functional analysis of mutations in the glucose-6-phosphate transporter that cause glycogen storage disease type Ib. Molecular Genetics and Metabolism, 2008, 95, 220-223.	1.1	13
46	Recent development and gene therapy for glycogen storage disease type Ia. Liver Research, 2017, 1, 174-180.	1.4	12
47	Glycogen storage disease type Ia in Argentina: two novel glucose-6-phosphatase mutations affecting protein stability. Molecular Genetics and Metabolism, 2004, 83, 276-279.	1.1	11
48	Increased scavenger receptor class B type I-mediated cellular cholesterol efflux and antioxidant capacity in the sera of glycogen storage disease type Ia patients. Molecular Genetics and Metabolism, 2006, 89, 233-238.	1.1	11
49	Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia. Biochemical and Biophysical Research Communications, 2020, 522, 1-7.	2.1	11
50	Glycogen Storage Disease Type Ia in Canines: A Model for Human Metabolic and Genetic Liver Disease. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	10
51	An evolutionary approach to optimizing glucoseâ€6â€phosphataseâ€Î± enzymatic activity for gene therapy of glycogen storage disease type Ia. Journal of Inherited Metabolic Disease, 2019, 42, 470-479.	3.6	9
52	Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumorâ€developing stage. Journal of Inherited Metabolic Disease, 2019, 42, 459-469.	3.6	9
53	Treatment of newborn G6pc mice with bone marrow-derived myelomonocytes induces liver repair. Journal of Hepatology, 2011, 55, 1263-1271.	3.7	8
54	Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia. Biochemical and Biophysical Research Communications, 2020, 527, 824-830.	2.1	8

#	Article	IF	Citations
55	Renal Disease in Type I Glycogen Storage Disease. , 2009, , 693-708.		2
56	Response letter. Journal of Inherited Metabolic Disease, 2018, 41, 915-915.	3.6	1